Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
07/2012
07/12/2012US20120177632 Methods of optimizing disease treatment
07/12/2012US20120177599 Compositions and methods for treatment, diagnosis and prognonis of mesothelioma
07/12/2012US20120177597 Compositions and methods of alteration of autoimmune diseases
07/12/2012US20120177596 METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES
07/12/2012US20120177595 Multimeric il-15 soluble fusion molecules and methods of making and using same
07/12/2012US20120177581 Bystander immune suppression as a predictor for response to a vaccine
07/12/2012US20120177579 Metal Abstraction Peptide (MAP) Tag and Associated Methods
07/12/2012US20120177575 Fas (apo-1,cd95) targeted platforms for intracellular drug delivery
07/12/2012US20120177568 Novel meditopes and related meditope-monoclonal antibody delivery systems, synthesis and therapeutic uses thereof
07/12/2012US20120177567 Methods of Treating Pediatric Acute Lymphoblastic Leukemia with an Anti-CD22 Immunotoxin
07/12/2012US20120177566 Membrane resident peptide in anti-cancer peptides causes tumor cell necrosis rather than apoptosis of cancer cells
07/12/2012DE102011008153A1 Preparing monoclonal antibody comprises immunizing mice with alpha synuclein peptide, removing and fusing B-lymphocytes with myeloma cell line, selecting fusion product peptide in cell culture vessel, selecting immunoglobulin and isolating
07/12/2012CA2824277A1 Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
07/12/2012CA2823908A1 Method for selecting patient to be given drug for treating septicemia
07/12/2012CA2823776A1 Plasma kallikrein binding proteins
07/12/2012CA2823747A1 Liposome formulation suitable for treating or preventing tuberculosis
07/12/2012CA2823549A1 Methods of treating age-related macular degeneration
07/12/2012CA2822481A1 A pharmaceutical composition of a complex of an anti-dig antibody and digoxigenin that is conjugated to a peptide
07/12/2012CA2821995A1 Monomeric and multimeric immunogenic peptides
07/12/2012CA2821926A1 Anti-il-12/il-23 antibodies and uses thereof
07/11/2012EP2474557A2 Anti-CD79b antibodies and immunoconjugates and methods of use
07/11/2012EP2474556A2 APCDD1 inhibitors for treating, diagnosing or detecting cancer
07/11/2012EP2474322A1 Products for prophylaxis and/or treatment of viral diseases and method of making and using same
07/11/2012EP2474317A1 Treatment of conditions involving demyelination
07/11/2012EP2474311A2 Method for treating th17 inflammatory disease through inhibition of vascular endothelial growth factor receptors and pharmaceutical composition therefor
07/11/2012EP2473602A1 Protein glycosylation
07/11/2012EP2473599A1 Bovine herpesvirus vaccine
07/11/2012EP2473530A1 Monoclonal antibodies against gonadotropin-releasing hormone receptor
07/11/2012EP2473529A1 Clec14a inhibitors
07/11/2012EP2473528A1 Stable formulations of polypeptides and uses thereof
07/11/2012EP2473525A2 Monoclonal antibodies against glycoprotein of ebola sudan boniface virus
07/11/2012EP2473191A1 Antibody coformulations
07/11/2012EP2473190A1 Heterologous prime-boost immunization regimen against bluetongue virus
07/11/2012EP2473189A2 Methods of reducing virucidal activity in pcv-2 compositions and pcv-2 compositions with an improved immunogenicity
07/11/2012EP2473188A1 Protein matrix vaccines of improved immunogenicity
07/11/2012EP2473187A1 Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
07/11/2012EP2473186A1 Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof
07/11/2012EP2473185A1 Treatment of neurological or neurodegenerative disorders
07/11/2012EP2233501B1 Humanized anti-cd34 monoclonal antibody, the preparation and uses thereof
07/11/2012EP2089053B1 Hpv antigen fusion protein vaccine compositions and uses thereof
07/11/2012EP2034015B1 Immunostimulatory oligonucleotide and pharmaceutical application thereof
07/11/2012EP2032161B1 L3v los vaccines
07/11/2012EP2019686B1 Combined mucosal and parenteral immunization against hiv
07/11/2012EP2001459B1 Methods and compositions for inducing an immune response to hiv and models for testing
07/11/2012EP1960434B1 Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
07/11/2012EP1767216B1 Drug having regulatory cell ligand contained in liposome
07/11/2012EP1766059B1 Influenza hemagglutinin and neuraminidase variants
07/11/2012EP1567188B1 Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases
07/11/2012EP1505981B1 Utilization of inhibitors of egfr-mediated signal transduction for the treatment of benign prostatic hyperplasia (bph)/prostatic hypertrophy
07/11/2012EP1259547B1 High potency recombinant antibodies and method for producing them
07/11/2012EP1169456B1 Recombinant production of Clostridium difficile Toxin A or Toxin B
07/11/2012CN1934255B Combination therapy for the treatment of ocular neovascular disorders
07/11/2012CN102575283A Diagnosis and treatment of cell proliferation and differentiation disorders based on the FMN 2 gene
07/11/2012CN102575256A Genetically modified sequences encoding plasmodium vivax antigens
07/11/2012CN102575232A Simian adenovirus 41 and uses thereof
07/11/2012CN102574925A Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications
07/11/2012CN102574918A Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
07/11/2012CN102574917A Pharmaceutical composition containing anti-HB-EGF antibody as active ingredient
07/11/2012CN102574916A Human recombinant monoclonal antibody that specifically binds to VCAM-1 and inhibits adhesion and transmigration between leukocytes and endothelial cells
07/11/2012CN102574915A Antibodies that specifically bind to A beta oligomers and use thereof
07/11/2012CN102574914A Improved anti-serum albumin binding single variable domains
07/11/2012CN102574910A Antibody composition with altered fab sialylation
07/11/2012CN102574908A Targeting tissue factor to activated platelets
07/11/2012CN102574905A HLA-G alpha 1 multimers and pharmaceutical uses thereof
07/11/2012CN102574897A Chimaeric protein
07/11/2012CN102573909A Anti-angiogenesis therapy for the treatment of previously treated breast cancer
07/11/2012CN102573908A Anti-gcc antibody molecules and related compositions and methods
07/11/2012CN102573907A Compositions and methods to treat acute myelogenous leukemia
07/11/2012CN102573906A Dual inhibition of immunophilin/cyclophilin and EMMPRIN immunoglobulin receptor superfamily members
07/11/2012CN102573905A Antibody design using anti-lipid antibody crystal structures
07/11/2012CN102573904A Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof
07/11/2012CN102573903A Composition for treating HBV infection
07/11/2012CN102573902A Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
07/11/2012CN102573901A Recombinant avian paramyxovirus vaccine and method for making and using thereof
07/11/2012CN102573900A New vaccine formulations comprising saponin-containing adjuvants
07/11/2012CN102573899A Methods of reducing virucidal activity in PCV-2 compositions and PCV-2 compositions with an improved immunogenicity
07/11/2012CN102573898A Herpes virus backbone for viral vaccine and vaccine based thereon
07/11/2012CN102573897A Nebulizable tuberculosis vaccine for transnasal administration comprising paramyxovirus vector
07/11/2012CN102573896A Compositions and methods for immunodominant antigens of mycobacterium tuberculosis
07/11/2012CN102573895A Methods, compositions, and kits for reducing anti-antibody responses
07/11/2012CN102573894A 疫苗 Vaccine
07/11/2012CN102573893A Cardiovascular related uses of IL-1beta antibodies and binding fragments thereof
07/11/2012CN102573891A Polymer particles and uses thereof
07/11/2012CN102573855A Modulation of axon degeneration
07/11/2012CN102573850A Screening method and therapy with agonists of DDAH I
07/11/2012CN102573802A Immunomodulatory compositions comprising a polymer matrix and an oil phase
07/11/2012CN102573800A Ophthalmic drug delivery system containing phospholipid and cholesterol
07/11/2012CN102573799A Pharmaceutical composition containing medicament-containing fine particles and method for producing same
07/11/2012CN102559707A Peste des petits ruminants virus H and F protein antigenic epitope gene fragment, and expression and application thereof
07/11/2012CN102559693A Vaccine adjuvant CCL28 as well as preparation method and application thereof
07/11/2012CN102559689A Prawn complement 1q binding protein and application thereof
07/11/2012CN102559644A Antidotes for factor XA inhibitors and methods of using the same
07/11/2012CN102559636A Antibody fusion protein used for leukemia and autoimmune disease and preparation method thereof
07/11/2012CN102559615A Preparation method of EV71 vaccine and vaccine prepared by preparation method
07/11/2012CN102559614A Classical swine fever vaccine and preparation method thereof
07/11/2012CN102559613A Malignant malaria vaccine and preparation method thereof
07/11/2012CN102559612A Recombinant newcastle disease virus LaSota vaccine strain for expressing Nipah virus encephalitis G-protein
07/11/2012CN102559610A Recombined duck virus enteritis viral vaccine strain CCTCC for expressing bird flu virus hemagglutinin (HA) gene (rDEVus78Ha) as well as establishing method and application thereof
07/11/2012CN102559609A Recombined adenovirus vaccine for preventing AIDS
07/11/2012CN102559606A A16 type strain of Coxsackie virus and application of the strain
1 ... 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 ... 1823